Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1

Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 141-141

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Novartis AG CH Switzerland (CH) Maastricht University NL Netherlands (NL) University of California, San Diego US United States (USA) (US)

How to cite

APA:

Rech, J., Reinhardt, M., Kavanaugh, A., Geusens, P., & Mpofu, S. (2017). Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1. (pp. 141-141).

MLA:

Rech, Jürgen, et al. "Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1." 2017. 141-141.

BibTeX: Download